VIIV-HEALTHCARE
2.12.2020 10:35:16 CET | Business Wire | Press release
ViiV Healthcare and Shutterstock Studios today announced the launch of a new online photo gallery ‘HIV in View’ , produced by Shutterstock in collaboration with ViiV Healthcare. The collection, curated with the support of people living with HIV, leverages Shutterstock’s global network of over one million creators to deliver a repository of high-resolution images depicting what it means to live with HIV today. Across four countries (the United Kingdom, Kenya, Uruguay, Portugal), people living with HIV stepped forward to be among the first photographed for this gallery, embarking on a shared ambition to help shift the world’s perception of HIV and move away from outdated stereotypes. From World AIDS Day 2020, the gallery will be free for all to access and use in projects, campaigns and communications* in the hope that it will increase awareness around HIV and break down barriers to stigma that still exist.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201201005521/en/
Doreen Moracha, aged 28, from Nairobi, Kenya, one of the first people to be photographed for the gallery and HIV Advocate, said , “I am so proud to be one of the first people to be photographed for the ‘HIV in View’ gallery and to be part of a movement for change to represent real people living with HIV, their stories and experiences. Until the world sees HIV for what it really is, we are not going to make the progress we need to disrupt stereotypes of what it’s like to live with HIV. If my photographs can change just one person’s opinion of what it means to live with HIV today, I will know we are a step closer to reaching this goal.”
Today, living with HIV is a very different experience from just ten years ago. Advances in prevention, treatment and care mean that people living with HIV can live longer, healthier lives, with a person starting treatment at 20 years old now able to expect to see their 77th birthday.1 Despite these advances, people living with HIV face unique challenges that affect their quality of life every day. Stigma remains a stubbornly persistent threat to the health and well-being of many people living with HIV, and can often impact their ability to consistently access life-saving treatments and social support systems.2 In the battle to challenge the negative assumptions about HIV, shining a light on the truth can be a potent strategy. Sharing the true picture and experiences of people living with HIV is key to undermining stigma.
Deborah Waterhouse, CEO, ViiV Healthcare, said, “At ViiV Healthcare, our mission is to leave no person living with HIV behind and reducing HIV-related stigma is key to achieving this. For too long, the public has been presented with outdated representations of what it is to live with HIV. Working with Shutterstock has underlined how a lack of widely accessible, present-day HIV imagery continues to hold us back. With the launch of the ‘HIV in View’ gallery, people across the world can now download authentic photography for free. As a company, we are making a pledge to use images of real people living with HIV across all our platforms, where applicable, moving forward and we encourage others to do the same. Living with HIV has changed, and we invite the world to help us show this.”
Michael Carfagnini, GM Global Shutterstock Studios, said, “ViiV Healthcare’s work in continuing to fight HIV-related stigma until people living with HIV are understood and accepted sparked a unique opportunity for Shutterstock to collaborate through powerful visuals. There is always a need for authentic and fresh imagery accurately depicting what it's like to live with HIV. At Shutterstock, we strive to empower the world’s storytellers through our content and services such as those offered through our new Studios division enabling brands and agencies to tell their unique stories. This presented an opportunity to prove the effectiveness and adaptability of our global network of contributors who would be tasked with safely depicting this crucial story, in a much more challenging time to do photography and videography with a pandemic limiting production around the world. This project and the various teams involved both at Shutterstock and ViiV Healthcare truly demonstrated the impact passion brings to creative projects, and we saw the same quality from our contributors and people living with HIV featured in the imagery.”
The ‘HIV in View’ gallery is produced by Shutterstock and created in collaboration with ViiV Healthcare. All images can be downloaded royalty free here: https://www.shutterstock.com/explore/viiv-collaboration .
Notes to editor
*The HIV in View collection will be offered for free under Shutterstock’s standard license to use in projects, campaigns and communications. Users who require the enhanced license will be charged the higher license fee, of which 100% of the proceeds will be donated to (RED), a non-profit organisation helping fund the fight to end AIDS, at the discretion of Shutterstock. For additional information on the license comparison, visit: https://www.shutterstock.com/license-comparison .
About Shutterstock, Inc.
Shutterstock, Inc. (NYSE: SSTK ), directly and through its group subsidiaries, is a leading global provider of high-quality licensed photographs , vectors , illustrations , videos and music to businesses, marketing agencies and media organizations around the world. Working with its growing community of over 1 million contributors, Shutterstock adds hundreds of thousands of images each week, and currently has more than 350 million images and more than 20 million video clips available.
Headquartered in New York City, Shutterstock has offices around the world and customers in more than 150 countries. The company’s brands also include Bigstock , a value-oriented stock media offering; Shutterstock Custom, a custom content creation platform ; Offset, a high-end image collection ; PremiumBeat, a curated royalty-free music library ; and Shutterstock Editorial, a premier source of editorial images and videos for the world's media.
For more information, please visit www.shutterstock.com and follow Shutterstock on Twitter and on Facebook .
About ViiV Healthcare
ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV. Shionogi joined in October 2012. The company’s aims are to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.
For more information on the company, its management, portfolio, pipeline, and commitment, please visit www.viivhealthcare.com .
About GSK
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com/about-us .
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk Factors" in the company's Annual Report on Form 20-F for 2019 and as set out in GSK’s “Principal risks and uncertainties” section of the Q3 Results and any impacts of the COVID-19 pandemic.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
1. May et al. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. Available at: https://pubmed.ncbi.nlm.nih.gov/24556869/ Last accessed: December 2020.
2. Avert. HIV stigma and discrimination. Available at: https://www.avert.org/professionals/hiv-social-issues/stigma-discrimination Last accessed: December 2020.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201201005521/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release
Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
